Application of gallocatechin gallate and isoquercitrin

Abstract

In the present specification, disclosed is a method for preparing a gallocatechin gallate (Gallocatable Gallate), which comprises the steps of: preparing a gallocatechin gallate (Gallocatable Gallate; the invention relates to application of a composition for regulating blood sugar or keeping healthy blood sugar values, in particular to application of a composition for regulating blood sugar or keeping healthy blood sugar values, such as GCG and isoquercitrin (IQC) and application of the composition to preparation of a composition for regulating blood sugar or keeping healthy blood sugar values. In one aspect, the composition of the present invention comprises a complex component of gallocatechin gallate and isoquercitrin, can effectively inhibit gluconeogenesis in hepatocytes, and can effectively improve glucose delivery in differentiated adipocytes and muscle cells, thus exhibiting excellent blood glucose regulation efficacy.

Description

Technical Field

[0001] The present specification discloses the use of epigallocatechin gallate and isoquercetin. Background Art

[0002] Glucose is absorbed into the body through the intake, digestion and absorption process of food, and is also newly produced in liver cells through gluconeogenesis (gluconeogenesis). On the contrary, it is used as an energy source in cells with active energy metabolism such as nerve cells and muscle cells, or in fat cells, etc., the transportation of glucose to the inside of the cell is promoted for the purpose of storing excess energy, so the blood glucose concentration is reduced. After various processes, the blood glucose regulation achieves balance, but when the blood glucose regulation fails due to various reasons (for example, fasting blood glucose 126mg / dl or more), diabetes will occur. Diabetes not only becomes the cause of various metabolic diseases such as obesity, hyperlipidemia, and hypertension, but also is difficult to cure once it occurs, so that it is necessary to manage eating habits and living habits for life, so it is a disease that greatly reduces the quality of life. In response to this, the actual situation is that it is necessary to suppress the occurrence of diabetes or improve diabetes symptoms and prevent or improve metabolic disease complications and improve the development of health functional foods or pharmaceuticals of quality of life.

[0003] Patent document: (Patent document 1) Korean Patent KR2022-0145604A Summary of the invention

[0004] An object of the present invention is to provide a composition having excellent blood sugar regulating ability.

[0005] In order to achieve the above object, the present invention provides, in one aspect, a composition for regulating blood sugar or maintaining a healthy blood sugar value, comprising gallocatechin gallate (GCG) and isoquercetin (IQC) as active ingredients.

[0006] On the one hand, the composition of the present invention comprises a composite component of epigallocatechin gallate and isoquercetin, which can effectively inhibit gluconeogenesis in hepatocytes and effectively promote glucose transport in differentiated adipocytes and muscle cells, and thus has excellent blood sugar regulating efficacy. BRIEF DESCRIPTION OF THE DRAWINGS

[0007] Figure 1 The inhibitory effects of the expression of gluconeogenesis-related genes in hepatocytes were compared according to the composition ratio of a mixture of gallocatechin gallate (GCG) and isoquercetin (IQC) (AdiPhenon).

[0008] Figure 2 The effect of promoting glucose absorption in adipocytes according to the composition ratio of the mixture was compared.

[0009] Figure 3 The effects of promoting glucose transport into myocytes according to the composition ratio of the mixture were compared.

[0010] Figure 4 The changes in the expression of genes related to the citric acid cycle in adipocytes were compared according to the composition ratio of the mixture.

[0011] Figure 5 Comparison of changes in the expression of genes related to the citric acid cycle in myocytes according to the composition ratio of the mixture.

[0012] Figure 6 The changes in intracellular lactate accumulation according to the mixture treatment were compared.

[0013] Figure 7 The gluconeogenesis gene expression inhibitory effect was compared according to the detailed composition ratio of the mixture.

[0014] Figure 8 The effects of promoting glucose absorption in adipocytes according to the detailed composition ratios of the mixtures were compared.

[0015] Fig. 9 The effects of promoting glucose uptake into muscle cells according to the detailed composition ratios of the mixtures were compared.

[0016] exist Figures 1 to 9 The experimental groups with statistically significant differences (P<0.05) are indicated by different marks. DETAILED DESCRIPTION

[0017] Hereinafter, the present invention will be described in detail.

[0018] The present invention relates to a composition for regulating blood sugar or maintaining a healthy blood sugar level, comprising gallocatechin gallate (GCG) and isoquercetin (IQC).

[0019] In an exemplary implementation example, the epigallocatechin gallate and isoquercetin may be included in a weight ratio of 9:1 or more, 8:2 or more, 7:3 or more, 6:4 or more, 5:5 or more, or 4:6 or more, and may be included in a weight ratio of 1:9 or less or 2:8 or less. For example, the epigallocatechin gallate and isoquercetin may be included in a weight ratio of 9:1 to 1:9, but is not limited thereto.

[0020] In an exemplary implementation example, the epigallocatechin gallate and isoquercetin can be included in a weight ratio of 1:1 or more, 1:1.1 or more, 1:1.2 or more, 1:1.3 or more, 1:1.4 or more, 1:1.5 or more, 1:1.6 or more, 1:1.7 or more, 1:1.8 or more, 1:1.9 or more, 1:2.0 or more, 1:2.1 or more, 1:2.2 or more, and can be included in a weight ratio of less than 1:9, less than 1:8, less than 1:7, less than 1:6, less than 1:5, less than 1:4, less than 1:3.5, less than 1:3.4, less than 1:3.3, less than 1:3.2, less than 1:3.1, less than 1:3, less than 1:2.9, less than 1:2.8, less than 1:2.7, less than 1:2.6 or less than 1:2.5. When the epigallocatechin gallate and isoquercetin are included in the weight ratio, blood sugar can be effectively regulated. For example, the epigallocatechin gallate and isoquercetin can be included in a weight ratio of 1:1 to 1:9 or 1:1.5 to 1:4, but is not limited thereto.

[0021] In this specification, the term "apply" means providing the composition to an applicable subject by any appropriate method, including administration, application, absorption and ingestion, etc. In this case, the applicable subject means all animals such as humans, monkeys, dogs, goats, pigs or mice to which the composition can be applied.

[0022] In an exemplary implementation example, the blood sugar regulation may be a decrease in blood sugar. The active ingredients of the composition may inhibit the decomposition of sugar in the blood, or promote the cellular absorption of glucose in the blood.

[0023] The glucose concentration in the blood is regulated by the influx of glucose and the balance of production, consumption and storage. When the glucose concentration decreases during fasting, if hypoglycemia is sensed in the pancreatic α cells, glucagon is secreted to decompose the glycogen stored in the liver cells or to synthesize glucose from acetyl-CoA in reverse. Such a process is called gluconeogenesis, which is inhibited by insulin secreted when full. When the insulin signaling system is disturbed for some reason, and even if insulin is present, insulin cannot perform its function normally (insulin resistance), if gluconeogenesis cannot be blocked by insulin, glucose continues to be produced in the liver cells, which may be linked to hyperglycemia.

[0024] In an exemplary implementation, the composition can be characterized as being suitable for use in a subject in need of reducing gluconeogenesis in hepatocytes.

[0025] In an exemplary implementation, the composition may be characterized in that it is suitable for a subject in need of reducing the expression of a gluconeogenesis-related gene, and the gluconeogenesis-related gene may be a PEPCK (Phosphoenol Pyruvate Carboxy Kinase) or a G6Pase (Glucose-6-Photase) gene.

[0026] In an exemplary implementation, the composition can be applied to a subject in need of increasing glucose absorption and / or transport in adipocytes or muscle cells.

[0027] In an exemplary implementation, the composition may be characterized in that it is suitable for a subject in need of increasing the expression of a citric acid cycle constituent gene, and the citric acid cycle constituent gene may be isocitrate dehydrogenase (IDH) or MD (Malate Dehydrogenase).

[0028] In an exemplary implementation, the composition can be applied to a subject in need of inhibiting intracellular lactic acid accumulation.

[0029] In an exemplary implementation, the composition can be applied to a subject in need of promoting intracellular aerobic energy metabolism.

[0030] In this specification, the term "prevention" means all actions to inhibit or delay diabetes, diabetic complications or glucose metabolism disorders through the use of the pharmaceutical composition. The term "treatment" means all actions to improve or favorably change the symptoms of suspected and onset individuals with diabetes, diabetic complications or glucose metabolism disorders through the use of the pharmaceutical composition.

[0031] The term "improvement" used in the present specification refers to all behaviors in which diabetes, diabetic complications or glucose metabolism disorders are improved or favorably changed by application of the composition.

[0032] In an exemplary implementation, the composition may be a pharmaceutical composition for preventing or treating diabetes, diabetic complications or glucose metabolism disorders.

[0033] In an exemplary implementation, the composition may be a non-therapeutic oral composition for preventing or improving diabetes, diabetic complications or glucose metabolism disorders.

[0034] In an exemplary implementation, the composition may be a food composition for maintaining healthy blood sugar levels.

[0035] Diabetes as described in this specification refers to a disease in which the balance between insulin sensitivity and insulin secretion in the body is broken, that is, insulin deficiency or decreased insulin sensitivity, so that the sugar in the blood cannot be used and the blood sugar cannot be regulated, and glucose is excreted in the urine. The diabetic complications can be divided into acute complications and chronic complications. The acute complications can be exemplified by ketoacidemia, hyperosmotic hyperglycemia syndrome, hypoglycemia, etc., and chronic complications can be exemplified by macrovascular complications such as coronary artery disease, cerebrovascular disease, peripheral vascular disease, etc., capillary complications such as diabetic membrane disease, diabetic nephropathy, diabetic neuropathy, etc., diabetic foot lesions, etc., but are not limited thereto.

[0036] In an exemplary implementation example, the daily applicable amount of the active ingredient of the composition can be 5 mg / kg or more, 6 mg / kg or more, 7 mg / kg or more, 8 mg / kg or more, 9 mg / kg or more, 10 mg / kg or more, 20 mg / kg or more, 30 mg / kg or more, 40 mg / kg or more, 50 mg / kg or more, 60 mg / kg or more, 70 mg / kg or more, 80 mg / kg or more, 90 mg / kg or more, 100 mg / kg or more, 1 g / kg or more, 2 g / kg or more, 3 g / kg or more, 4 g / kg or more, 5 g / kg or more, or 6 g / kg or more, and can be less than 60 g / kg, less than 59 g / kg, less than 58 g / kg, less than 57 g / kg, less than 56 g / kg, less than 55 g / kg, less than 54 g / kg, less than 53 g / kg, less than 52 g / kg, or less than 51 g / kg. It can be that the blood sugar regulating effect is excellent under the applicable amount, the blood sugar regulating effect is small when it is lower than the applicable amount, and toxicity and other problems occur when it is higher than the applicable amount. The application can also be applied once a day to multiple times. For example, it can be applied 2 to 24 times a day, 1 to 2 times a day, 1 to 6 times a week, 1 to 10 times a week, 1 to 15 times a week, 1 to 3 times a week, or 1 to 12 times a year, but is not limited to this.

[0037] In an exemplary implementation example, the pharmaceutical composition can be provided in all dosage forms suitable for local application. For example, it can be administered orally, transdermally, intravenously, intramuscularly, or subcutaneously. As an example, the pharmaceutical composition can be an injection, a skin external solution, a suspension, an emulsion, a gel, a patch, or a spray, but is not limited thereto. The dosage form can be easily prepared according to the usual methods in the art, and surfactants, excipients, hydrating agents, emulsifying agents, suspending agents, salts or buffers for osmotic pressure regulation, colorants, spices, stabilizers, preservatives, preservatives, or other commonly used adjuvants can be appropriately used.

[0038] In an exemplary implementation, the active ingredient of the pharmaceutical composition may vary according to the subject's age, sex, weight, pathological condition and its severity, route of administration or the prescriber's judgment. The appropriate dosage based on these factors is within the level of those skilled in the art.

[0039] In an exemplary implementation example, when the composition is used as an additive for health functional food, it can be added as it is or used together with other food or food ingredients, and can be used appropriately according to the usual method. The mixing amount of the active ingredient can be appropriately determined according to the purpose of use such as prevention, health or treatment. The dosage form of the health functional food can be not only in the form of powder, granules, pills, tablets, capsules, but also any form of general food or beverage is possible.

[0040] In an exemplary implementation example, there is no particular limitation on the type of health functional food. Examples of foods to which the composition can be added include meat, biscuits, noodles, chewing gum, dairy products including ice cream, various soups, beverages, teas, oral liquids, alcoholic beverages, and vitamin complexes, etc., including all foods in the usual sense.

[0041] In an exemplary implementation example, when preparing the health functional food or beverage, the composition can be added in an amount of 15 parts by weight or less, preferably 10 parts by weight or less, relative to 100 parts by weight of the raw material. However, when long-term intake is for the purpose of health and hygiene or for the purpose of health regulation, the amount can be below the range.

[0042] In an exemplary implementation example, the beverage in the health functional food can include various flavorings or natural carbohydrates as additional ingredients like ordinary beverages. The above-mentioned natural carbohydrates can be monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, polysaccharides such as dextrin and cyclodextrin, sugar alcohols such as xylitol, sorbitol, and erythritol. As sweeteners, natural sweeteners such as thaumatin and stevia extract, saccharin, synthetic sweeteners such as aspartame, etc. can be used. The proportion of the natural carbohydrates can be about 0.01 to 0.04g per 100ml beverage according to the present invention, preferably about 0.02 to 0.03g, but is not limited thereto.

[0043] In an exemplary implementation example, in addition to the above, the health functional food according to the present invention may contain various nutrients, vitamins, electrolytes, flavoring agents, colorants, pectin acid and its salts, alginic acid and its salts, organic acids, protective colloid thickeners, pH regulators, stabilizers, preservatives, glycerol, alcohol, and carbonating agents used in carbonated beverages. In addition, the health functional food according to the present invention may contain pulp for the preparation of natural fruit juices, fruit juice drinks, and vegetable drinks. These ingredients can be used independently or in combination. The proportion of these additives is not limited, but is generally selected from the range of 0.01 to 0.1 parts by weight compared to every 100 parts by weight of the health functional food according to the present invention.

[0044] In another aspect, the present invention is a method for regulating blood sugar, comprising administering to a subject a composition comprising an effective amount of epigallocatechin gallate (GCG) and isoquercitrin (IQC).

[0045] In another aspect, the present invention is a method for maintaining healthy blood sugar levels comprising administering to a subject a composition comprising an effective amount of epigallocatechin gallate (GCG) and isoquercitrin (IQC).

[0046] In yet another aspect, the present invention is a use of epigallocatechin gallate (GCG) and isoquercitrin (IQC) for preparing a composition for regulating blood sugar or maintaining healthy blood sugar levels.

[0047] In yet another aspect, the present invention provides gallocatechin gallate (GCG) and isoquercitrin (IQC) for blood sugar regulation or maintenance of healthy blood sugar levels.

[0048] In yet another aspect, the present invention is a non-therapeutic use of gallocatechin gallate (GCG) and isoquercitrin (IQC) for blood sugar regulation or maintenance of healthy blood sugar values.

[0049] The following examples are given to more specifically describe the configuration and effects of the present invention. However, the following examples are provided for the purpose of illustration only to help understanding of the present invention, and the scope and range of the present invention are not limited thereto.

[0050] [Example]

[0051] [Example 1]

[0052] Comparison of the inhibitory effect of gallocatechin gallate (GCG) and isoquercitrin (IQC) on gluconeogenesis in hepatocytes treated with AdiPhenon

[0053] The present inventors have confirmed whether a mixture of gallocatechin gallate (GCG) and isoquercitrin (IQC) (AdiPhenon) can inhibit gluconeogenesis in hepatocytes. Specifically, HepG2 cells purchased from ATCC were cultured in Roswell Park Memorial Institute-1640 medium (Sigma Aldrich) containing 10% fetal bovine serum (Gibco) and 1% penicillin / streptomycin (P / S; Sigma Aldrich). In order to confirm the gluconeogenesis inhibitory effect according to the composition ratio of GCG and IQC, HepG2 cells were treated with complexes of various ratios (GCG:IQC=10:0 to 0:10) at a total concentration of 100 μg / ml for 24 hours. As a positive control group, insulin (10 nM, Sigma Aldrich), which is known to inhibit gluconeogenesis, was used. The cells were then washed with Phosphate Buffered Saline (PBS; Sigma Aldrich) and RNA was extracted using the TaKaRa MiniBEST Universal RNA Extraction Kit (Takara Bio). The same amount of RNA (1 mg) was used to extract RNA using RevertAid 1 stcDNA was synthesized using RevertAid First-Strand cDNA Synthesis Kit (Thermo Fisher Scientific), and the expression of PEPCK (Phosphoenol Pyruvate Carboxy Kinase) and G6Pase (Glucose-6-Photase), which are the rate-limiting enzymes of gluconeogenesis, was observed using CFX96 thermocycler (Bio-Rad). Figure 1 ).

[0054] The results, such as Figure 1 As shown, the mixture suppressed the expression of gluconeogenesis-related genes compared with the single substance treatment group regardless of the composition ratio, and the expression suppression of the gene in the mixture was most excellent at a ratio of GCG:IQC=4:6 to 2:8. That is, it was confirmed that the mixture can effectively inhibit gluconeogenesis in hepatocytes.

[0055] [Example 2]

[0056] Effect of promoting glucose transport in adipocytes and muscle cells treated with the mixture

[0057] In order to confirm another main mechanism of blood sugar regulation, whether the mixture can promote glucose absorption in adipocytes and myocytes was confirmed. Specifically, mouse-derived preadipocytes (3T3-L1) and myoblasts (C2C12) were purchased from ATCC. 3T3-L1 cells were cultured in Dulbecco's Modified Eagle's Medium (DMEM; SigmaAldrich) containing 10% bovine calf serum (Gibco, calf serum), 1% P / S, and C2C12 cells were cultured in DMEM containing 10% FBS, 1% P / S. Differentiation to adipocytes was induced by the following method. After 3T3-L1 cells were cultured to 100% fullness in the culture dish, they were treated in DMEM containing dexamethasone (1mM, Sigma Aldrich), insulin (10mg / ml, Sigma Aldrich), 3-isobutyl-1-methylxanthine (0.5mM, Sigma Aldrich), FBS (10%), and P / S (1%) for 48 hours. After that, DMEM containing 10% FBS, 10mg / ml insulin, and 1% P / S was cultured for 14 days at intervals of two days to induce differentiation into complete adipocytes. Differentiation into muscle cells was also achieved by proliferating C2C12 cells to 100% fullness in the culture dish and then differentiating them for 7 days with DMEM culture medium containing 2% horse serum (HS, Gibco) and 1% P / S. The culture medium was changed every day during the differentiation process. In order to confirm the transport of glucose in differentiated adipocytes and myocytes, starvation was induced one day before the experiment with serum-free, low-glucose DMEM (Sigma Aldrich) containing only 1% P / S. The mixtures of various composition ratios were then treated for 24 hours as in Example 1. In order to confirm the interaction with insulin, an experimental group treated with insulin (100 nM) was additionally generated. After 24 hours, the amount of glucose transported into the cells was quantified using a Glucose Uptake Assay kit (colorimetric, abcam). Quantification was performed using a Tecan Infinite M200 Pro Microplate Reader (ab 412nm).

[0058] The results, such as Figure 2 as well as Figure 3As shown, it was confirmed that the mixtures of various composition ratios can effectively promote the intracellular uptake of glucose in adipocytes and myocytes, and this effect is doubled in the presence of insulin. In addition, it was confirmed that the glucose transport enhancement effect of the mixture was the most excellent at a ratio of GCG:IQC=4:6 to 2:8.

[0059] [Example 3]

[0060] Activation of the citric acid cycle in cells treated with the mixture

[0061] Glucose that flows into the cell is used as an energy source or stored in the form of glycogen, fatty acids, etc. depending on the cell. In particular, when stored as fatty acids / neutral lipids in fat cells, it may cause obesity due to increased body fat, so it is necessary to confirm whether the absorbed glucose is used as an energy source. Glucose is decomposed into two molecules of pyruvate through the glycolysis process, and pyruvate is converted into acetyl-CoA through additional metabolism. Acetyl-CoA is used to synthesize ATP in the mitochondrial electron transport system through the citric acid cycle.

[0062] In order to investigate whether the mixture treatment can activate intracellular energy metabolism, adipocytes and muscle cells were differentiated by the method mentioned in Example 2, and then the mixtures of various composition ratios were treated for 24 hours. Then, RNA was extracted and cDNA was synthesized by the method mentioned in Example 1, and the expression of genes constituting the citric acid cycle was confirmed.

[0063] The results, such as Figure 4 as well as Figure 5 As shown, it was confirmed that in adipocytes ( Figure 4 ) and muscle cells ( Figure 5 ) The citric acid cycle gene expression promoting effect of the mixture treated with various composition ratios was confirmed. In addition, the effect of the mixture was confirmed to be most excellent at a GCG:IQC composition ratio of 3:7 to 2:8.

[0064] On the other hand, even if the expression of genes constituting the citric acid cycle increases, if there is insufficient oxygen or mitochondria in the cell, the citric acid cycle cannot operate smoothly. In this case, pyruvate replaces the production of acetyl-CoA and produces a small amount of ATP through the lactic acid fermentation process, during which lactic acid accumulates, which causes fatigue in the cell. In this regard, if the degree of lactic acid accumulation in the cell is compared, the aerobic energy metabolism activity in the cell can be indirectly confirmed. If the cell is treated with CoCl2, the stabilization of HIF-1α is induced, and the cell has the illusion of hypoxia. At this time, the cell lacks oxygen (illusion) and does not go through the oxidative phosphorylation process using mitochondria, and uses lactic acid fermentation that does not consume oxygen to generate ATP.

[0065] To this end, differentiated adipocytes and muscle cells were treated with CoCl2 (100 μM, Sigma Aldrich) for 12 hours to induce hypoxia, and then treated with a mixture of GCG:IQC=3:7 and 2:8, which shows the most excellent synergistic effect in the field of energy metabolism, for 24 hours to measure the amount of lactic acid accumulated in the cells (L-lactate Assay Kit (L-lactic acid detection kit, Colorimetric, abcam).

[0066] The results, such as Figure 6 As shown, the experimental results that the mixture inhibited intracellular lactate accumulation in addition to the promotion of citric acid cycle gene expression indicate that the mixture can promote intracellular aerobic energy metabolism.

[0067] [Example 4]

[0068] Comparison of effects according to mixture ratio

[0069] In order to study the optimal ratio of each mixture composition ratio for best synergy, the experiments of Examples 1 and 2 were repeated after treatment with various composition ratios in the ratio range of GCG:IQC=4:6 (about 1:1.5) to 2:8 (about 1:4).

[0070] The results, such as Figures 7 to 9 As shown, it was confirmed that the GCG:IQC ratio was between 1:2.1 and 1:2.7, and more specifically, the most excellent synergistic effect was exhibited at 1:2.4.

[0071] The present disclosure is additionally illustrated by the following implementation examples which do not limit the claims.

[0072] Implementation Example 1. Use of gallocatechin gallate (GCG) and isoquercetin (IQC) for preparing a composition for regulating blood sugar or maintaining healthy blood sugar values.

[0073] Implementation Example 2. As the use of Implementation Example 1, the composition comprises gallocatechin gallate (GCG) and isoquercitrin (IQC) in a weight ratio of 9:1 to 1:9.

[0074] Implementation Example 3. As the use of Implementation Example 1 or 2, the composition is characterized in that it is suitable for a subject in need of reducing gluconeogenesis in hepatocytes.

[0075] Implementation Example 4. As the use of Implementation Examples 1 to 3, the composition is characterized in that it is suitable for a subject in need of reducing the expression of gluconeogenesis-related genes.

[0076] Implementation Example 5. As the use of Implementation Examples 1 to 4, the composition is characterized in that it is suitable for a subject that needs to increase glucose absorption and / or transport in fat cells or muscle cells.

[0077] Implementation Example 6. As the use of Implementation Examples 1 to 5, the composition is characterized in that it is suitable for a subject in need of increasing the expression of genes constituting the citric acid cycle.

[0078] Implementation Example 7. As the use of Implementation Examples 1 to 6, the composition is characterized in that it is suitable for a subject in need of inhibiting intracellular lactic acid accumulation.

[0079] Implementation Example 8. As the use of Implementation Examples 1 to 7, the composition is characterized in that it is suitable for a subject in need of promoting intracellular aerobic energy metabolism.

[0080] Implementation Example 9. As the use of Implementation Examples 1 to 8, the composition can be a pharmaceutical composition for preventing or treating diabetes, diabetic complications or glucose metabolism disorders.

[0081] Implementation Example 10. As the use of Implementation Examples 1 to 9, the composition can be a food composition for maintaining healthy blood sugar values.

Claims

1. Use of gallocatechin gallate (GCG) and isoquercetin (IQC) for preparing a composition for blood sugar regulation or maintaining healthy blood sugar values.

2. The use according to claim 1, wherein The composition includes gallocatechin gallate (GCG) and isoquercitrin (IQC) in a weight ratio of 9:1 to 1:

9.

3. The use according to claim 1, wherein The composition is suitable for a subject in need of reducing gluconeogenesis in hepatocytes.

4. The use according to claim 1, wherein The composition is suitable for a subject in need of reducing the expression of gluconeogenesis-related genes.

5. The use according to claim 1, wherein The composition is suitable for a subject in need of increasing glucose absorption and / or transport in adipocytes or muscle cells.

6. The use according to claim 1, wherein The composition is suitable for a subject in need of increasing the expression of genes constituting the citric acid cycle.

7. The use according to claim 1, wherein The composition is suitable for a subject in need of inhibiting intracellular lactic acid accumulation.

8. The use according to claim 1, wherein The composition is suitable for a subject in need of promoting intracellular aerobic energy metabolism.

9. The use according to claim 1, wherein The composition is a pharmaceutical composition for preventing or treating diabetes, diabetic complications or sugar metabolism disorders.

10. The use according to claim 1, wherein The composition is a food composition for maintaining healthy blood sugar levels.

Images